{"id":"https://openalex.org/W2564972773","doi":"https://doi.org/10.1128/aac.01968-16","title":"Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory","display_name":"Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory","alternate_titles":[],"publication_year":2016,"publication_date":"2016-12-13","ids":{"openalex":"https://openalex.org/W2564972773","doi":"https://doi.org/10.1128/aac.01968-16","mag":"2564972773","pmid":"https://pubmed.ncbi.nlm.nih.gov/27956417","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5278725"},"language":"en","primary_location":{"id":"doi:10.1128/aac.01968-16","doi":"https://doi.org/10.1128/aac.01968-16","is_oa":true,"landing_page_url":"https://doi.org/10.1128/aac.01968-16","pdf_url":"https://aac.asm.org/content/aac/61/2/e01968-16.full.pdf","source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2564972773"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://aac.asm.org/content/aac/61/2/e01968-16.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5056048003","display_name":"Adam C. Belley","orcid":"https://orcid.org/0000-0002-5090-5938","observed_orcids":["https://orcid.org/0000-0002-5090-5938"]},"institutions":[{"id":"https://openalex.org/I4387152963","display_name":"Medicines Company (United States)","ror":"https://ror.org/0564rh245","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619","https://openalex.org/I4387152963"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adam Belley","raw_affiliation_strings":["The Medicines Company, Parsippany, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Medicines Company, Parsippany, New Jersey, USA","institution_ids":["https://openalex.org/I4387152963"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108417421","display_name":"Richard A. Robson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126461","display_name":"Christchurch Clinical Studies Trust","ror":"https://ror.org/02wccra50","country_code":"NZ","type":"facility","lineage":["https://openalex.org/I4210126461","https://openalex.org/I4405259085"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"Richard Robson","raw_affiliation_strings":["Christchurch Clinical Studies Trust, Christchurch, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Christchurch Clinical Studies Trust, Christchurch, New Zealand","institution_ids":["https://openalex.org/I4210126461"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111622988","display_name":"John L. Francis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270336","display_name":"AdventHealth","ror":"https://ror.org/00gqase94","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4405270336"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John L. Francis","raw_affiliation_strings":["Florida Hospital Center for Thrombosis Research, Winter Park, Florida, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Florida Hospital Center for Thrombosis Research, Winter Park, Florida, USA","institution_ids":["https://openalex.org/I4405270336"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051534860","display_name":"Dorothy M. Adcock","orcid":"https://orcid.org/0000-0002-0182-6272","observed_orcids":["https://orcid.org/0000-0002-0182-6272"]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dorothy M. Adcock","raw_affiliation_strings":["Colorado Coagulation, Laboratory Corporation of America Holdings, Englewood, Colorado, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Colorado Coagulation, Laboratory Corporation of America Holdings, Englewood, Colorado, USA","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070903702","display_name":"Stefan Tiefenbacher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stefan Tiefenbacher","raw_affiliation_strings":["Colorado Coagulation, Laboratory Corporation of America Holdings, Englewood, Colorado, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Colorado Coagulation, Laboratory Corporation of America Holdings, Englewood, Colorado, USA","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037239328","display_name":"Christopher M. Rubino","orcid":"https://orcid.org/0000-0003-3172-0847","observed_orcids":["https://orcid.org/0000-0003-3172-0847"]},"institutions":[{"id":"https://openalex.org/I4210118651","display_name":"Institute for Clinical Pharmacodynamics (United States)","ror":"https://ror.org/02gck7e73","country_code":"US","type":"company","lineage":["https://openalex.org/I4210118651"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher M. Rubino","raw_affiliation_strings":["Institute for Clinical Pharmacodynamics, Latham, New York, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute for Clinical Pharmacodynamics, Latham, New York, USA","institution_ids":["https://openalex.org/I4210118651"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063290824","display_name":"Greg Moeck","orcid":"https://orcid.org/0000-0001-7827-7227","observed_orcids":["https://orcid.org/0000-0001-7827-7227"]},"institutions":[{"id":"https://openalex.org/I4387152963","display_name":"Medicines Company (United States)","ror":"https://ror.org/0564rh245","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619","https://openalex.org/I4387152963"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Greg Moeck","raw_affiliation_strings":["The Medicines Company, Parsippany, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Medicines Company, Parsippany, New Jersey, USA","institution_ids":["https://openalex.org/I4387152963"]}]},{"author_position":"middle","author":{"id":null,"display_name":"David Sylvester","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152963","display_name":"Medicines Company (United States)","ror":"https://ror.org/0564rh245","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619","https://openalex.org/I4387152963"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Sylvester","raw_affiliation_strings":["The Medicines Company, Parsippany, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Medicines Company, Parsippany, New Jersey, USA","institution_ids":["https://openalex.org/I4387152963"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112068381","display_name":"Michael N. Dudley","orcid":"https://orcid.org/0009-0007-0068-6283","observed_orcids":["https://orcid.org/0009-0007-0068-6283"]},"institutions":[{"id":"https://openalex.org/I4387152963","display_name":"Medicines Company (United States)","ror":"https://ror.org/0564rh245","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619","https://openalex.org/I4387152963"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael N. Dudley","raw_affiliation_strings":["The Medicines Company, Parsippany, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Medicines Company, Parsippany, New Jersey, USA","institution_ids":["https://openalex.org/I4387152963"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109171208","display_name":"J. Loutit","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152963","display_name":"Medicines Company (United States)","ror":"https://ror.org/0564rh245","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619","https://openalex.org/I4387152963"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffery Loutit","raw_affiliation_strings":["The Medicines Company, Parsippany, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Medicines Company, Parsippany, New Jersey, USA","institution_ids":["https://openalex.org/I4387152963"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.7911,"has_fulltext":true,"cited_by_count":18,"citation_normalized_percentile":{"value":0.71165518,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":"61","issue":"2","first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10881","display_name":"Blood Coagulation and Thrombosis Mechanisms","score":0.5419999957084656,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10881","display_name":"Blood Coagulation and Thrombosis Mechanisms","score":0.5419999957084656,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11314","display_name":"Clinical Laboratory Practices and Quality Control","score":0.37229999899864197,"subfield":{"id":"https://openalex.org/subfields/3607","display_name":"Medical Laboratory Technology"},"field":{"id":"https://openalex.org/fields/36","display_name":"Health Professions"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.007600000128149986,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oritavancin","display_name":"oritavancin","score":1.0},{"id":"https://openalex.org/keywords/lipoglycopeptide-antibiotics","display_name":"lipoglycopeptide antibiotics","score":0.9150000214576721},{"id":"https://openalex.org/keywords/coagulation-test-interference","display_name":"coagulation test interference","score":0.8690000176429749},{"id":"https://openalex.org/keywords/prothrombin-time","display_name":"prothrombin time","score":0.7049999833106995},{"id":"https://openalex.org/keywords/activated-partial-thromboplastin-time","display_name":"activated partial thromboplastin time","score":0.9819999933242798},{"id":"https://openalex.org/keywords/activated-protein-c-resistance","display_name":"activated protein C resistance","score":0.6959999799728394},{"id":"https://openalex.org/keywords/anti-factor-xa-assay","display_name":"anti-factor Xa assay","score":0.8420000076293945},{"id":"https://openalex.org/keywords/d-dimer","display_name":"D-dimer","score":0.7680000066757202},{"id":"https://openalex.org/keywords/lipopeptide-antibiotics","display_name":"lipopeptide antibiotics","score":0.46399998664855957}],"concepts":[{"id":"https://openalex.org/C2778261982","wikidata":"https://www.wikidata.org/wiki/Q1755136","display_name":"Partial thromboplastin time","level":3,"score":0.7977414131164551},{"id":"https://openalex.org/C2780434524","wikidata":"https://www.wikidata.org/wiki/Q1144385","display_name":"Prothrombin time","level":2,"score":0.680427074432373},{"id":"https://openalex.org/C2780077467","wikidata":"https://www.wikidata.org/wiki/Q2520736","display_name":"Thrombin time","level":4,"score":0.5670705437660217},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5397745966911316},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5254361033439636},{"id":"https://openalex.org/C2777987278","wikidata":"https://www.wikidata.org/wiki/Q4677454","display_name":"Activated clotting time","level":3,"score":0.5027058124542236},{"id":"https://openalex.org/C2779216453","wikidata":"https://www.wikidata.org/wiki/Q489957","display_name":"Bleeding time","level":4,"score":0.4929523468017578},{"id":"https://openalex.org/C2778382381","wikidata":"https://www.wikidata.org/wiki/Q179217","display_name":"Coagulation","level":2,"score":0.41739070415496826},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39002811908721924},{"id":"https://openalex.org/C2777557582","wikidata":"https://www.wikidata.org/wiki/Q190016","display_name":"Heparin","level":2,"score":0.3844602406024933},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.34637850522994995},{"id":"https://openalex.org/C89560881","wikidata":"https://www.wikidata.org/wiki/Q101026","display_name":"Platelet","level":2,"score":0.18610763549804688},{"id":"https://openalex.org/C2993802102","wikidata":"https://www.wikidata.org/wiki/Q101026","display_name":"Platelet aggregation","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000077427","descriptor_name":"Lipoglycopeptides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001777","descriptor_name":"Blood Coagulation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D001780","descriptor_name":"Blood Coagulation Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006020","descriptor_name":"Glycopeptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006487","descriptor_name":"Hemostasis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014640","descriptor_name":"Vancomycin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1128/aac.01968-16","doi":"https://doi.org/10.1128/aac.01968-16","is_oa":true,"landing_page_url":"https://doi.org/10.1128/aac.01968-16","pdf_url":"https://aac.asm.org/content/aac/61/2/e01968-16.full.pdf","source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:4363227","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5278725","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmid:27956417","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27956417","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial agents and chemotherapy","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:pubmedcentral.nih.gov:5278725","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5278725/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrob Agents Chemother","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1128/aac.01968-16","doi":"https://doi.org/10.1128/aac.01968-16","is_oa":true,"landing_page_url":"https://doi.org/10.1128/aac.01968-16","pdf_url":"https://aac.asm.org/content/aac/61/2/e01968-16.full.pdf","source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320315666","display_name":"Medicines Company","ror":null},{"id":"https://openalex.org/F4320332163","display_name":"U.S. Food and Drug Administration","ror":"https://ror.org/034xvzb47"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2564972773.pdf","grobid_xml":"https://content.openalex.org/works/W2564972773.grobid-xml"},"referenced_works_count":10,"referenced_works":["https://openalex.org/W1500970473","https://openalex.org/W1800717743","https://openalex.org/W1964024657","https://openalex.org/W1984998403","https://openalex.org/W2005195188","https://openalex.org/W2087963748","https://openalex.org/W2104660584","https://openalex.org/W2119300753","https://openalex.org/W2161621663","https://openalex.org/W2560442233"],"related_works":["https://openalex.org/W2560442233","https://openalex.org/W2104660584","https://openalex.org/W1800717743","https://openalex.org/W2054769245","https://openalex.org/W1983806856","https://openalex.org/W2110498167","https://openalex.org/W3214955129","https://openalex.org/W2319027422","https://openalex.org/W1763813325","https://openalex.org/W1754932965"],"abstract_inverted_index":{"Previous":[0],"studies":[1],"have":[2],"shown":[3],"that":[4,124],"some":[5,17,214],"lipoglycopeptide":[6,26],"and":[7,42,83,112,140,161,230],"lipopeptide":[8],"antimicrobial":[9],"agents":[10],"may":[11],"cause":[12],"falsely":[13,210],"elevated":[14,211],"values":[15,212],"for":[16,115],"phospholipid-dependent":[18],"coagulation":[19,29,199,215],"tests.":[20],"The":[21,165,221],"effect":[22,97],"of":[23,50,56,72,119,129,151,181,189,206,213,223],"oritavancin,":[24,130],"a":[25,44,51,126,184,203],"antibiotic,":[27],"on":[28,98,197,225],"test":[30,90,152,232],"results":[31,233],"was":[32,168],"explored":[33],"using":[34],"pooled":[35],"human":[36],"plasma":[37,63],"samples":[38],"spiked":[39],"with":[40,64,145,183],"drug":[41],"in":[43,58,132,173,179,201],"clinical":[45],"study":[46],"after":[47,241],"an":[48,113],"infusion":[49],"single":[52,127,204],"1,200-mg":[53],"intravenous":[54],"dose":[55,128,205],"oritavancin":[57,65,94,193,207,224],"normal":[59,236],"healthy":[60],"volunteers.":[61],"Pooled":[62],"added":[66],"ex":[67],"vivo":[68],"showed":[69],"concentration-dependent":[70],"prolongation":[71],"prothrombin":[73],"time/international":[74],"normalized":[75],"ratio":[76],"(PT/INR),":[77],"activated":[78,100,137],"partial":[79],"thromboplastin":[80],"time":[81,88,143,186],"(aPTT),":[82],"dilute":[84],"Russell":[85],"viper":[86],"venom":[87],"(DRVVT)":[89],"results.":[91],"In":[92,122],"contrast,":[93],"had":[95],"no":[96,195],"the":[99,116,146,198,231],"protein":[101],"C":[102],"resistance":[103],"assay,":[104],"chromogenic":[105],"anti-factor":[106],"Xa":[107],"assay":[108,167],"(anti-FXa),":[109],"thrombin":[110],"time,":[111,139],"immunoassay":[114],"laboratory":[117],"diagnosis":[118],"heparin-induced":[120],"thrombocytopenia.":[121],"participants":[123],"received":[125],"elevations":[131,172],"PT/INR":[133],"result,":[134],"aPTT,":[135],"DRVVT,":[136],"clotting":[138,142],"silica":[141],"occurred,":[144],"maximum":[147,185],"times":[148,240],"to":[149,155,187,218,235],"resolution":[150,188],"interference":[153,222],"determined":[154],"be":[156],"12,":[157],"120,":[158],"72,":[159],"24,":[160],"18":[162],"h,":[163],"respectively.":[164],"anti-FXa":[166],"unaffected,":[169],"whereas":[170],"transient":[171],"D":[174],"dimer":[175],"levels":[176],"were":[177],"observed":[178],"30%":[180],"participants,":[182],"72":[190],"h.":[191],"Although":[192],"has":[194],"impact":[196],"system":[200],"vivo,":[202],"can":[208],"produce":[209],"tests":[216,227],"used":[217],"monitor":[219],"hemostasis.":[220],"affected":[226],"is":[228],"transient,":[229],"revert":[234],"ranges":[237],"within":[238],"specified":[239],"dosing.":[242]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2564972773","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-19T14:11:59.513116","created_date":"2017-01-06T00:00:00"}
